Literature DB >> 18498548

Shall we use Avastin or Lucentis for ocular neovascularization?

Peep V Algvere, Anders Kvanta, Stefan Seregard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18498548     DOI： 10.1111/j.1755-3768.2008.01317.x

Source DB:  PubMed          Journal:  Acta Ophthalmol        ISSN： 1755-375X            Impact factor:   3.761


× No keyword cloud information.
  3 in total

Review 1.  Anti-VEGF therapies and blood pressure: more than meets the eye.

Authors:  Frank Enseleit; Stephan Michels; Frank Ruschitzka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

2.  Intracellular bevacizumab reduces phagocytotic uptake in RPE cells.

Authors:  Alexa Klettner; Friederike Möhle; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-19       Impact factor: 3.117

Review 3.  Advanced drug delivery and targeting technologies for the ocular diseases.

Authors:  Jaleh Barar; Ayuob Aghanejad; Marziyeh Fathi; Yadollah Omidi
Journal:  Bioimpacts       Date:  2016-03-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.